For patients with stage I HER2+ breast cancer, the importance of appropriate de-escalation for those who may be at lower risk requires further examination. Sara Tolaney, MD, Dana Farber Cancer Institute, Boston, MA, evaluates data on adjuvant treatment for stage I HER2-positive breast cancer, who despite being early-stage, still represent a risk for disease recurrence. Dr Tolaney touches on the APT trial (NCT00542451) which evaluated an abbreviated chemotherapy regimen to patients with stage I disease. Also discussed is the findings of the ATEMPT trial (NCT01853748) investigating T-DM1 versus paclitaxel plus trastuzumab in stage I HER2+ breast cancer. This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.

свернуть